Table 1

Baseline Characteristics of the Study Population (n = 339)

VariablesAll Patients (n = 339)Transfemoral (n = 162)Transapical (n = 177)p Value
Age (yrs)81 ± 883 ± 880 ± 80.009
Male sex152 (44.8)91 (56.1)61 (34.5)<0.0001
BMI (kg/m2)26 ± 526 ± 526 ± 50.934
Diabetes79 (23.3)37 (22.8)42 (23.7)0.898
Dyslipidemia241 (71.1)104 (64.2)137 (77.4)0.020
Hypertension252 (74.3)102 (62.9)150 (84.7)<0.0001
Current smokers20 (5.9)8 (4.9)12 (6.8)0.645
NYHA functional class
 I–II29 (8.6)11 (6.8)18 (10.2)0.332
 III–IV308 (90.9)150 (92.6)158 (89.3)
Chronic atrial fibrillation/flutter115 (33.9)66 (40.7)49 (27.7)0.012
Coronary artery disease234 (69.0)110 (67.9)124 (70.1)0.723
Previous myocardial infarction173 (51.0)82 (50.6)91 (51.4)0.913
Previous PCI99 (29.2)47 (29.0)52 (29.4)1.00
Prior coronary artery bypass grafting116 (34.2)49 (30.2)67 (37.9)0.169
Cerebrovascular disease77 (22.7)27 (16.7)50 (28.2)0.013
Peripheral vascular disease120 (35.4)31 (19.1)89 (50.3)<0.0001
COPD100 (29.5)45 (27.8)55 (31.1)0.551
Creatinine (μmol/l)119 ± 83124 ± 85113 ± 810.232
eGFR <60 ml/min191 (56.3)86 (53.1)104 (58.8)0.325
Dialysis10 (2.9)7 (4.3)3 (1.7)0.203
STS-PROM score (%)9.8 ± 6.49.0 ± 5.810.5 ± 6.90.034
Porcelain aorta61 (17.9)28 (17.3)33 (18.6)0.779
Frailty85 (25.1)42 (25.9)43 (24.3)0.802
Pulmonary hypertension84 (25.0)35 (21.6)49 (27.7)0.256
Severe mitral regurgitation27 (8.0)18 (11.1)9 (5.1)0.045
Mean aortic gradient (mm Hg)46 ± 1748 ± 1844 ± 170.079
Aortic valve area (cm2)0.63 ± 0.170.63 ± 0.160.63 ± 0.180.928
LVEF (%)55 ± 1455 ± 1456 ± 140.721
LVEF <40%54 (15.9)26 (16.1)28 (15.8)1.00

Values are expressed as n (%) or mean ± SD.

BMI = body mass index; COPD = chronic obstructive pulmonary disease; eGFR = estimated glomerular filtration rate; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; STS-PROM = Society of Thoracic Surgeons Predicted Risk Of Mortality.